Analyst firms · Jefferies · MRNA

Jefferies MRNA price target and rating history

Moderna Inc. (MRNA) · Health Care

Jefferies rates Moderna Inc. (MRNA) Hold with a $30 price target, as of its latest action on Dec 12, 2025. It has published 5 rating actions on MRNA since July 2021, including 1 upgrade and 1 downgrade. Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. Jefferies's $30 is 47% below that.

Current rating

Hold

Price target

$30

Median target, all firms

$57

Actions on MRNA

5

Jefferies price target on MRNA

Every Jefferies rating on MRNA

• Dec 12, 2025
  InitiateJefferies starts coverage at Hold, price target $30
• Sep 13, 2024
  DowngradeJefferies downgrades to Hold from Buy, price target $120 to $65
• Dec 19, 2022
  UpgradeJefferies upgrades to Buy from Hold, price target $170 to $275
• Nov 5, 2021
  ReiterateJefferies cuts its price target to $325 from $375, keeps Hold
• Jul 15, 2021
  ReiterateJefferies raises its price target to $250 from $170, keeps Hold

How other firms rate MRNA

Each firm's latest rating and stated target in the last 12 months.

Questions about Jefferies and MRNA

What is Jefferies's price target for MRNA?

Jefferies's latest stated price target for Moderna Inc. (MRNA) is $30, from its action on Dec 12, 2025.

What is Jefferies's rating on MRNA?

Jefferies rates MRNA Hold, a neutral rating, as of Dec 12, 2025.

When did Jefferies last change its view on MRNA?

On Dec 12, 2025, Jefferies starts coverage at Hold, price target $30.

How does Jefferies's MRNA target compare with other analysts?

Across 6 firms with a MRNA price target in the last 12 months, the median target is $57. Jefferies's $30 is 47% below that.

More MRNA rating histories

• William Blair3
• Argus Research3
• Wolfe Research3
• BofA Securities3
• Barclays4
• UBS3
• HSBC5
• Oppenheimer3
• Deutsche Bank7
• TD Cowen4
• Leerink Partners5
• Morgan Stanley5
• Piper Sandler3

All Jefferies ratingsMRNA news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.